Serelaxin

Last updated
Serelaxin
Clinical data
Trade names Reasanz
Pregnancy
category
  • N/A
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
  • Investigational
Identifiers
  • L-Serine, L-α-aspartyl-L-seryl-L-tryptophyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-valylL-isoleucyl-L-lysyl-L-leucyl-L-cysteinylglycyl-L-arginyl-L-α-glutamyl-L-leucyl-L-valyl-L- arginyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-cysteinylglycyl-L- methionyl-L-seryl-L-threonyl-L-tryptophyl-, cyclic (11→11'),(23→24')-bis(disulfide) with 5-oxo-L-prolyl-L-leucyl-L-tyrosyl-L-seryl-L-alanyl-L-leucyl-L-alanyl-L-asparaginyl-L-lysyl-L- cysteinyl-L-cysteinyl-L-histidyl-L-valylglycyl-L-cysteinyl-L-threonyl-L-lysyl-L-arginyl-L- seryl-L-leucyl-L-alanyl-L-arginyl-L-phenylalanyl-L-cysteine cyclic (10'→15')-disulfide
CAS Number
ChemSpider
  • none
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C256H408N74O74S8
Molar mass 5963.00 g·mol−1

Serelaxin (brand name Reasanz; developmental code name RLX-030) is a medication which is marketed in Russia for the treatment of acute heart failure (AHF), targeting the relaxin receptor. [1] It was also under development in other places in the world, including in the United States, Europe, and Asia, but ultimately was not marketed in these areas. [1]

Serelaxin is a recombinant form of human relaxin-2, a hormone that (among other functions) is produced during pregnancy and mediates the haemodynamic changes that occur during this time, [2] [3] such as increased blood output of the heart and blood flow in the kidney. [4] Human-relaxin-2 mediates vasodilation (widening of blood vessels) by increasing the production of nitric oxide (NO), a potent vasodilator. [5] Activation of the relaxin receptor RXFP1 activates several enzymes in a phosphorylation cascade that eventually results in the activation of NO synthase in endothelial cells and the subsequent production of NO. [6] Relaxin can also bind to a secondary receptor, endothelial B receptor,[ clarification needed ] which is upregulated as a result of the previous pathway. [7] Relaxin binding to endothelial B receptor on endothelial cells also induces vasodilation. [8]

Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin. [9] In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing creatinine clearance, [10] which is a measure of kidney function, as well as increased renal blood flow. [8] Relaxin also functions as a cardiac stimulant. [6] Studies have demonstrated that relaxin increases calcium sensitivity of cardiac myofilaments as well as increasing phosphorylation of the myofilaments by protein kinase C (PKC). [11] These modifications both function to increase the force generated by the myofilaments without increasing the energy consumption of the cardiac myocytes. [11] Thus relaxin and serelaxin can increase stroke volume, the amount of blood pumped per heart beat, without increasing the energy demand on the already strained heart of acute heart failure patients.

Acute heart failure

Serelaxin has undergone clinical trials in patients with acute heart failure, [12] conducted by Novartis. Serelaxin has completed several clinical trials as a therapy for AHF. Phase I trials examined safety and tolerability, [13] while phase II trials evaluated its haemodynamic effects and symptom relief. The Pre-RELAX-AHF phase II trial administered a dose of 30 µg/kg/day and showed a decrease in blood pressure, improved dyspnoea, and increased renal blood flow. [8] In phase III the RELAX-AHF trial gave a 48hr intravenous infusion of the same dose. [14] It significantly improved patients' dyspnoea, resulted in a 30% reduction in worsening of heart failure symptoms, a decreased hospital stay and a reduction in signs and symptoms of congestion. [12] [15] The FDA granted serelaxin "breakthrough therapy" designation, meant to expedite the development and review of drugs for life-threatening conditions. [16] On 22 March 2017, Novartis announced that the global Phase III study of serelaxin in patients with acute heart failure did not meet its primary endpoints. [17]

Related Research Articles

<span class="mw-page-title-main">ACE inhibitor</span> Class of medications used primarily to treat high blood pressure

Angiotensin-converting-enzyme inhibitors are a class of medication used primarily for the treatment of high blood pressure and heart failure. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

<span class="mw-page-title-main">Adrenergic receptor</span> Class of G protein-coupled receptors

The adrenergic receptors or adrenoceptors are a class of G protein-coupled receptors that are targets of many catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) produced by the body, but also many medications like beta blockers, beta-2 (β2) agonists and alpha-2 (α2) agonists, which are used to treat high blood pressure and asthma, for example.

<span class="mw-page-title-main">Cardiac muscle</span> Muscular tissue of heart in vertebrates

Cardiac muscle is one of three types of vertebrate muscle tissues, with the other two being skeletal muscle and smooth muscle. It is an involuntary, striated muscle that constitutes the main tissue of the wall of the heart. The cardiac muscle (myocardium) forms a thick middle layer between the outer layer of the heart wall and the inner layer, with blood supplied via the coronary circulation. It is composed of individual cardiac muscle cells joined by intercalated discs, and encased by collagen fibers and other substances that form the extracellular matrix.

<span class="mw-page-title-main">Atrial natriuretic peptide</span> Cardiac hormone which increases renal sodium excretion

Atrial natriuretic peptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac atria that in humans is encoded by the NPPA gene. Natriuretic peptides are a family of hormone/paracrine factors that are structurally related. The main function of ANP is causing a reduction in expanded extracellular fluid (ECF) volume by increasing renal sodium excretion. ANP is synthesized and secreted by cardiac muscle cells in the walls of the atria in the heart. These cells contain volume receptors which respond to increased stretching of the atrial wall due to increased atrial blood volume.

<span class="mw-page-title-main">Vasodilation</span> Widening of blood vessels

Vasodilation, also known as vasorelaxation, is the widening of blood vessels. It results from relaxation of smooth muscle cells within the vessel walls, in particular in the large veins, large arteries, and smaller arterioles. The process is the opposite of vasoconstriction, which is the narrowing of blood vessels.

<span class="mw-page-title-main">Haemodynamic response</span>

In haemodynamics, the body must respond to physical activities, external temperature, and other factors by homeostatically adjusting its blood flow to deliver nutrients such as oxygen and glucose to stressed tissues and allow them to function. Haemodynamic response (HR) allows the rapid delivery of blood to active neuronal tissues. The brain consumes large amounts of energy but does not have a reservoir of stored energy substrates. Since higher processes in the brain occur almost constantly, cerebral blood flow is essential for the maintenance of neurons, astrocytes, and other cells of the brain. This coupling between neuronal activity and blood flow is also referred to as neurovascular coupling.

<span class="mw-page-title-main">Relaxin</span> Protein hormone

Relaxin is a protein hormone of about 6000 Da, first described in 1926 by Frederick Hisaw.

<span class="mw-page-title-main">Carvedilol</span> Oral blood-pressure medication

Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure (CHF), and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.

Adenosine A<sub>1</sub> receptor Cell surface receptor found in humans

The adenosine A1 receptor (A1AR) is one member of the adenosine receptor group of G protein-coupled receptors with adenosine as endogenous ligand.

<span class="mw-page-title-main">Milrinone</span> Chemical compound

Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.

<span class="mw-page-title-main">Nebivolol</span> Chemical compound

Nebivolol is a beta blocker used to treat high blood pressure and heart failure. As with other β-blockers, it is generally a less preferred treatment for high blood pressure. It may be used by itself or with other blood pressure medication. It is taken by mouth.

Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family.

<span class="mw-page-title-main">Takotsubo cardiomyopathy</span> Sudden temporary weakening of the heart muscle

Takotsubo cardiomyopathy or takotsubo syndrome (TTS), also known as stress cardiomyopathy, is a type of non-ischemic cardiomyopathy in which there is a sudden temporary weakening of the muscular portion of the heart. It usually appears after a significant stressor, either physical or emotional; when caused by the latter, the condition is sometimes called broken heart syndrome. Examples of physical stressors that can cause TTS are sepsis, shock, subarachnoid hemorrhage, and pheochromocytoma. Emotional stressors include bereavement, divorce, or the loss of a job. Reviews suggest that of patients diagnosed with the condition, about 70–80% recently experienced a major stressor, including 41–50% with a physical stressor and 26–30% with an emotional stressor. TTS can also appear in patients who have not experienced major stressors.

Biological functions of nitric oxide are roles that nitric oxide plays within biology.

<span class="mw-page-title-main">Riociguat</span> Chemical compound

Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylate cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators. The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.

<span class="mw-page-title-main">Coronary perfusion pressure</span>

Coronary perfusion pressure (CPP) refers to the pressure gradient that drives coronary blood pressure. The heart's function is to perfuse blood to the body; however, the heart's own myocardium must, itself, be supplied for its own muscle function. The heart is supplied by coronary vessels, and therefore CPP is the blood pressure within those vessels. If pressures are too low in the coronary vasculature, then the myocardium risks ischemia with subsequent myocardial infarction or cardiogenic shock.

<span class="mw-page-title-main">Omecamtiv mecarbil</span> Chemical compound

Omecamtiv mecarbil (INN), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is being studied for a potential role in the treatment of left ventricular systolic heart failure.

CXL 1020 is an experimental drug that is being investigated as a treatment for acute decompensated heart failure. CXL 1020 functions as a nitroxyl donor; nitroxyl is the reduced, protonated version of nitric oxide. Nitroxyl is capable of enhancing left ventricular contractility without increasing heart rate by modifying normal Ca2+ cycling through the sarcoplasmic reticulum as well as increasing the sensitivity of cardiac myofilaments to Ca2+.

The β3 adrenergic receptor agonist or β3-adrenoceptor agonist, also known as β3-AR agonist, are a class of medicine that bind selectively to β3-adrenergic receptors.

<span class="mw-page-title-main">Brain natriuretic peptide 32</span> Hormone secreted in the heart

Brain natriuretic peptide 32 (BNP), also known as B-type natriuretic peptide, is a hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. Along with NT-proBNP, BNP is one of two natriuretic peptides.

References

  1. 1 2 "Serelaxin - Novartis". Adis Insight. Springer Nature Switzerland AG.
  2. ↑ Spreitzer H (4 March 2013). "Neue Wirkstoffe – Serelaxin". Österreichische Apothekerzeitung (in German) (5/2013): 36.
  3. ↑ Einecke D (23 November 2012). "Schwangerschaftshormon gegen Herzschwäche" [Pregnancy hormone against heart failure]. Ärzte-Zeitung (in German).
  4. ↑ Conrad KP (August 2011). "Maternal vasodilation in pregnancy: the emerging role of relaxin". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 301 (2): R267-75. doi:10.1152/ajpregu.00156.2011. PMC   3154715 . PMID   21613576.
  5. ↑ Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (January 2012). "The role of nitric oxide on endothelial function". Current Vascular Pharmacology. 10 (1): 4–18. doi:10.2174/157016112798829760. PMID   22112350.
  6. 1 2 Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ (January 2013). "Relaxin family peptides and their receptors". Physiological Reviews. 93 (1): 405–80. doi:10.1152/physrev.00001.2012. PMID   23303914.
  7. ↑ Miyares MA, Davis KA (October 2013). "Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure". P & T. 38 (10): 606–11. PMC   3875246 . PMID   24391379.
  8. 1 2 3 Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (June 2010). "Relaxin: review of biology and potential role in treating heart failure". Current Heart Failure Reports. 7 (2): 75–82. doi:10.1007/s11897-010-0010-z. PMC   2875472 . PMID   20424993.
  9. ↑ Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. (December 2009). "Relaxin, a pleiotropic vasodilator for the treatment of heart failure". Heart Failure Reviews. 14 (4): 321–9. doi:10.1007/s10741-008-9129-3. PMC   2772950 . PMID   19101795.
  10. ↑ Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al. (February 2014). "A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure". European Heart Journal. 35 (7): 431–41. doi:10.1093/eurheartj/eht459. PMC   3924183 . PMID   24255129.
  11. 1 2 Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG (July 2009). "Relaxin alters cardiac myofilament function through a PKC-dependent pathway". American Journal of Physiology. Heart and Circulatory Physiology. 297 (1): H29-36. doi:10.1152/ajpheart.00482.2008. PMID   19429819.
  12. ↑ Du XJ, Hewitson TD, Nguyen MN, Samuel CS (2014). "Therapeutic effects of serelaxin in acute heart failure". Circulation Journal. 78 (3): 542–52. doi: 10.1253/circj.cj-14-0014 . PMID   24451687.
  13. ↑ King A (January 2013). "Heart failure. Promising data for serelaxin". Nature Reviews. Cardiology. 10 (1): 3. doi: 10.1038/nrcardio.2012.174 . PMID   23165078. S2CID   2399731.
  14. ↑ Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, et al. (April 2014). "Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial". European Heart Journal. 35 (16): 1041–50. doi:10.1093/eurheartj/eht497. PMC   3992428 . PMID   24316514.
  15. ↑ "FDA grants breakthrough designation to Novartis' serelaxin (RLX030) for acute heart failure". Novartis Global. Archived from the original on 2 March 2014.
  16. ↑ "Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure". Global Novartis News Archive. Archived from the original on 10 July 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.